Volume 4.24 | Jun 21

LABORATORY RESEARCH

Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy
Scientists used the well-characterized 4T1 syngeneic, orthotopic breast cancer model to identify novel mechanisms of post-radiation metastasis. [Clin Cancer Res] Abstract

To Bind or Not to Bind – FoxA1 Determines Estrogen Receptor Action in Breast Cancer Progression
Researchers aimed to determine the dynamics of estrogen receptor binding and differences between more and less aggressive primary breast tumors and metastases. [Breast Cancer Res] Abstract

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Augments Binding of the c-Src Kinase SH3 Domain to Crk-Associated Substrate (p130Cas)
Researchers showed that among NSP family members, only BCAR3 augments the ability of p130Cas to bind the Src SH3 domain through an RPLPSPP motif in the p130Cas Src-binding domain. [J Biol Chem]
Abstract | Full Article

MicroRNA-632 Downregulates DNAJB6 in Breast Cancer
Scientists found that hsa-microRNA-632 (miR-632) targets the coding region of DNAJB6, and invasive and metastatic breast cancer cells express high levels of miR-632 compared with mammary epithelial cells. [Lab Invest] Abstract

Breast Cancer Cell Targeting by Prenylation Inhibitors Elucidated in Living Animals with a Bioluminescence Reporter
To determine which cell types can be targeted directly by distinct classes of prenylation inhibitors in vivo, researchers described the development and implementation of a sensitive and pharmacologically specific bioluminescence-based imaging reporter that is inducible by prenylation inhibitors. [Clin Cancer Res] Abstract

LEF-1 Regulates Proliferation and MMP-7 Transcription in Breast Cancer Cells
Investigators demonstrated that lymphoid enhancer binding factor-1 (LEF-1) is associated with regulation of the proliferation-associated cyclin D1 and a gene encoding matrix metalloproteinase-7 (MMP-7) in breast cancer cells. [Genes Cells] Abstract

Frondoside A Has an Anti-Invasive Effect by Inhibiting TPA-Induced MMP-9 Activation via NF-κB and AP-1 Signaling in Human Breast Cancer Cells
Researchers aimed to determine the anti-invasive activity of frondoside A against human breast cancer cells. They investigated the inhibitory effect of frondoside A on cell clonogenicity, invasion and migration in TPA-stimulated human breast cancer cells at non-cytotoxic concentrations. [Int J Oncol] Abstract

RL71, a Second-Generation Curcumin Analog, Induces Apoptosis and Downregulates Akt in ER-Negative Breast Cancer Cells
RL71 is a second-generation curcumin analog that exhibits potent cytotoxicity towards a variety of estrogen receptor (ER)-negative breast cancer cells. Researchers examined the mechanism of this anticancer activity in three different ER-negative breast cancer cell lines. [Int J Oncol] Abstract

CLINICAL RESEARCH

Clinically Used Breast Cancer Markers Such as Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Researchers investigated whether hormonal receptors and human epidermal growth factor receptor 2 change throughout tumor progression. [J Clin Oncol] Abstract

Methylation of HIN-1, RASSF1A, RIL and CDH13 in Breast Cancer Is Associated with Clinical Characteristics, but Only RASSF1A Methylation Is Associated with Outcome
To determine the impact of methylation on clinical outcome, researchers have conducted a large study with breast cancers for which time to first recurrence and overall survival are known. [BMC Cancer] Abstract

Clinical Trial at The Cancer Institute of New Jersey Focuses on New Drug for Metastatic Breast Cancer
Researchers at The Cancer Institute of New Jersey are enrolling patients for a clinical trial, which aims to evaluate a new drug for breast cancer that has spread in combination with two chemotherapy agents called doxorubicin and cyclophosphamide. [The Cancer Institute of New Jersey] Press Release

Oncomatrix, National Jewish Health and Case Western Reserve University Join Forces to Attack Invasive Tumors
Oncomatrix has licensed from National Jewish Health an intellectual property portfolio claiming the use of the human protein Cystatin-C to treat cancer. Oncomatrix will use Cystatin-C to develop biological drugs to treat pancreas and invasive breast tumors. [Business Wire] Press Release

Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Advanced and Metastatic Breast Cancers
Oncolytics Biotech Inc. announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston will sponsor and conduct a randomized Phase II study of REOLYSIN^® in patients with advanced or metastatic breast cancer. [Oncolytics Biotech Inc.]
Press Release

ACR Pleased that AMA Breast Cancer Screening Position Recognizes Importance of Screening Beginning at Age 40
The American College of Radiology (ACR) is pleased that the American Medical Association (AMA), in updating its policy on breast cancer screening exams, “recognizes the mortality reduction benefit of screening mammography and supports its use as a tool to detect breast cancer” and “believes that beginning at the age of 40 years, all women should be eligible for screening mammography.” [American College of Radiology, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 2012 American Society for Cell Biology (ASCB) Annual Meeting
December 15-19, 2012
San Francisco, United States

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!